Takeda Pharmaceuticals makes major adjustments to its US market strategy.

According to recent media reports, Takeda is laying off 243 employees in the United States to cope with the market challenge of Trintellix losing its exclusive sales rights. However, Takeda also plans to hire more than 400 new positions to support the US launch and marketing of several potential new drugs.

AstraZeneca continues to deepen its presence in the Chinese market.

On January 16, CBMG announced an agreement with AstraZeneca, under which the latter will acquire CBMG's 50% stake in the development and commercialization rights of C-CAR031 in China. This will grant AstraZeneca exclusive rights to develop, manufacture, and commercialize C-CAR031 globally. Under the terms of the agreement, CBMG will be entitled to receive up to $630 million from AstraZeneca, including upfront payments for the GPC3 project in China, as well as development, regulatory, and sales milestone payments.

What other hot topics in the domestic and international pharmaceutical markets were worth noting in the past day? Let Amino Jun take you to find out.

/ 01 /
Market Express

1) AstraZeneca acquires remaining Chinese rights to Sibman's GPC3 CAR-T therapy

On January 16, CBMG announced an agreement with AstraZeneca, under which the latter will acquire CBMG's 50% stake in the development and commercialization rights of C-CAR031 in China. This will grant AstraZeneca exclusive rights to develop, manufacture, and commercialize C-CAR031 globally. Under the terms of the agreement, CBMG will be entitled to receive up to $630 million from AstraZeneca, including upfront payments for the GPC3 project in China, as well as development, regulatory, and sales milestone payments.

/ 02 /
Medical News

1) Eli Lilly's Mirikizumab injection receives clinical approval

On January 19, according to the CDE website, Eli Lilly's Mirikizumab injection received clinical approval for a study to treat moderate to severe active ulcerative colitis.

2) Xingqi Eye Drops SQ-24071 Receives Clinical Trial Approval

On January 19, according to the CDE website, Xingqi Eye Drops SQ-24071 eye drops received clinical approval and is intended to be used to slow the progression of myopia in children and adolescents.

3) Yingen Biotech's ADAM9 ADC Receives Clinical Trial Approval

On January 19, InnoBio announced that its independently developed ADAM9-targeting antibody-drug conjugate (ADC) DB-1317 has been officially approved by the CDE for Investigational New Drug (IND) clinical trials, allowing it to be used as a monotherapy in patients with advanced/metastatic malignant solid tumors.

4) Hengrui Medicine's lipoprotein (a) inhibitor is proposed for inclusion in the Breakthrough Therapy program.

On January 19, according to the CDE website, Hengrui Medicine's HRS-5346 is proposed to be included in the Breakthrough Therapy list for the treatment of elevated lipoprotein (a) levels.

5) Grand Pharmaceutical's RDC drugs have been submitted for market approval.

On January 19, Grand Pharmaceutical issued an announcement stating that its innovative investigational radionuclide conjugate (RDC) TLX591-CDx for the diagnosis of prostate cancer has recently submitted a New Drug Application (NDA) to the National Medical Products Administration (NMPA) and has been accepted.

/ 03 /
Overseas Pharmaceutical News

1) Takeda Pharmaceutical lays off employees in the United States

According to recent media reports, Takeda is laying off 243 employees in the United States to cope with the market challenge of Trintellix losing its exclusive sales rights. However, Takeda also plans to hire more than 400 new positions to support the US launch and marketing of several potential new drugs.

https://bydrug.pharmcube.com/news/detail/7924877bb50fdfda4082599bf919b11a